Hina Patel

Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non–Small Cell Lung Cancer

Louis Fehrenbacher, Joachim von Pawel, Keunchil Park et al. · Journal of Thoracic Oncology · 2018 · 261 citations · Full text

Medicine, Oncology, Pharmacology +12

Long-term survival in patients with advanced non–small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study

Joachim von Pawel, Rodolfo Bordoni, Miyako Satouchi et al. · European Journal of Cancer · 2018 · 106 citations

Medicine, Oncology, Pharmacotherapy +12

Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non–Small-Cell Lung Cancer

Martin Reck, Thomas Wehler, Francesco Orlandi et al. · Journal of Clinical Oncology · 2020 · 94 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting

Kari M. Morrissey, Mathilde Marchand, Hina Patel et al. · Cancer Chemotherapy and Pharmacology · 2019 · 89 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Continuous Etomidate Infusion for the Management of Severe Cushing Syndrome: Validation of a Standard Protocol

William Peppard, David Herrmann, Bradley R. Javorsky et al. · Journal of the Endocrine Society · 2018 · 72 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +11